RXRX
RECURSION PHARMACEUTICALS, INC.Marquee-fund ownership over time
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $6.28 | $2.89 | -54% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $6.28 | $2.89 | -54% |
| Millennium Management re-entered | Q4 2024(8Q snapshot) | 6Q | $6.91 | $2.89 | -58% |
| D.E. Shaw re-entered | Q2 2025(8Q snapshot) | 4Q | $4.25 | $2.89 | -32% |
| AQR Capital Management re-entered | Q2 2025(8Q snapshot) | 4Q | $4.25 | $2.89 | -32% |
| Renaissance Technologies | Q2 2026(8Q snapshot) | 1Q | $3.04 | $2.89 | -5% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | Q2 2026 | → $2.93 | -15% |
| Duquesne Family Office | Q4 2021 | Q2 2024 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at RECURSION PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40001856369-26-000023Jun 5, 2026
- Form 40002020969-26-000004Jun 5, 2026
- Form 40002060594-26-000003Jun 4, 2026
- Form 40001856094-26-000008Jun 4, 2026
- Form 40001856369-26-000019May 27, 2026
- Form 40002006495-26-000010May 19, 2026
- Form 40002020969-26-000002May 19, 2026
- Form 40001712276-26-000005May 19, 2026
- Form 40001856369-26-000017May 19, 2026
- Form 40001856369-26-000015May 8, 2026
- Form 40001856094-26-000005May 7, 2026
- Form 40001856369-26-000013Apr 24, 2026
- Form 40001712276-26-000003Apr 8, 2026
- Form 40001856369-26-000008Apr 8, 2026
- Form 40001856094-26-000003Apr 8, 2026
Fundamentals
XBRL · RECURSION PHARMACEUTICALS, INC.Annual figures sourced directly from RECURSION PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for RECURSION PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 6, 2026
- 8-KMaterial eventMay 6, 2026
- DEF 14AProxy statementApr 30, 2026
- 8-KMaterial eventApr 30, 2026
- 8-KMaterial eventMar 25, 2026
- 10-KAnnual reportFeb 25, 2026
- 8-KMaterial eventFeb 25, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventDec 8, 2025
- 8-KMaterial eventNov 26, 2025
- 10-QQuarterly reportNov 5, 2025
- 8-KMaterial eventNov 5, 2025
- 8-KMaterial eventOct 29, 2025
- 8-K/AMaterial event (amended)Aug 29, 2025
- 10-QQuarterly reportAug 5, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| AQR Capital Management | Q2 2026 | open | $2.93 | $2.89 | -1% |
| Renaissance Technologies | Q2 2026 | open | $3.04 | $2.89 | -5% |
| D.E. Shaw | Q1 2026 | open | $3.46 | $2.89 | -16% |
| Millennium Management | Q1 2026 | open | $3.46 | $2.89 | -16% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | $3.46 | $2.93 | -15% |
| D.E. Shaw | Q2 2025 | Q4 2025 | $4.25 | $4.14 | -3% |
| AQR Capital Management | Q2 2025 | Q1 2026 | $4.25 | $3.46 | -19% |
| Millennium Management | Q4 2024 | Q4 2025 | $6.91 | $4.14 | -40% |
| Citadel Advisors | Q3 2024 | open | $6.28 | $2.89 | -54% |
| Two Sigma Investments | Q3 2024 | open | $6.28 | $2.89 | -54% |
| Duquesne Family Office | Q4 2021 | Q2 2024 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.